These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Tumour necrosis factor alpha, lipid peroxidation and NO* are increased and associated with decreased free-radical scavenging enzymes in patients with Weill-Marchesani syndrome. Evereklioglu C; Turkoz Y; Calis M; Duygulu F; Karabulut AB Mediators Inflamm; 2004 Jun; 13(3):165-70. PubMed ID: 15223607 [TBL] [Abstract][Full Text] [Related]
48. Serum interleukin-8 as a serologic marker of activity in Behçet's disease. Gür-Toy G; Lenk N; Yalcin B; Aksaray S; Alli N Int J Dermatol; 2005 Aug; 44(8):657-60. PubMed ID: 16101867 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of leptin level and Ob gene polymorphism in patients with Behcet's disease. Okudan N; Acar H; Gökbel H; Mevlitoğlu I; Sari F Arch Dermatol Res; 2006 Aug; 298(3):127-30. PubMed ID: 16786343 [TBL] [Abstract][Full Text] [Related]
50. Increased advanced oxidation protein products in Behçet's disease: a new activity marker? Yazici C; Köse K; Caliş M; DemIr M; Kirnap M; Ateş F Br J Dermatol; 2004 Jul; 151(1):105-11. PubMed ID: 15270878 [TBL] [Abstract][Full Text] [Related]
51. Levels of soluble E-selectin in patients with active Behcet's disease. Sari RA; Kiziltunç A; Taysi S; Akdemir S; Gündoğdu M Clin Rheumatol; 2005 Feb; 24(1):55-9. PubMed ID: 15338451 [TBL] [Abstract][Full Text] [Related]
59. Influence of therapy on the antioxidant status in patients with melanoma. Gadjeva V; Dimov A; Georgieva N J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784 [TBL] [Abstract][Full Text] [Related]
60. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. Oztas MO; Onder M; Gurer MA; Bukan N; Sancak B Clin Exp Dermatol; 2005 Jan; 30(1):61-3. PubMed ID: 15663506 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]